Peptides for stimulant use disorder

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides for Stimulant Use Disorder: Normalizing Dopamine and Reducing Cravings Stimulant Use Disorder (StUD), encompassing addiction to substances like cocaine, methamphetamine, and prescription stimulants, affects millions globally, with limited...

Peptides for Stimulant Use Disorder: Normalizing Dopamine and Reducing Cravings

Stimulant Use Disorder (StUD), encompassing addiction to substances like cocaine, methamphetamine, and prescription stimulants, affects millions globally, with limited FDA-approved pharmacotherapies and high rates of relapse [1]. The core pathology of StUD involves profound dysregulation of the dopamine system, leading to intense cravings, anhedonia, and impaired executive function. Traditional interventions often focus on behavioral therapies, but the neurobiological underpinnings of StUD necessitate novel approaches that can restore dopamine homeostasis and mitigate neuroadaptations. Peptides offer a promising avenue by modulating reward pathways, neuroinflammation, and stress responses.

The neurobiology of StUD is characterized by chronic alterations in the mesolimbic dopamine system, which mediates reward and motivation. Repeated stimulant exposure leads to dopamine transporter dysfunction, reduced dopamine receptor sensitivity, and structural changes in brain regions involved in impulse control and decision-making [2]. Neuropeptides play a crucial role in regulating these processes. For instance, Cocaine- and Amphetamine-Regulated Transcript (CART) peptide is known to be involved in the actions of drugs of abuse, with studies confirming its role in modulating drug-seeking behaviors [3].

BPC-157, a stable gastric pentadecapeptide, is primarily recognized for its regenerative and cytoprotective properties. However, its influence extends significantly to the central nervous system, particularly its modulatory effects on the dopamine system. Animal studies have shown BPC-157 to attenuate chronic amphetamine-induced stereotypy and block the development of haloperidol-induced dopamine receptor supersensitivity, suggesting its potential in normalizing dopamine function disrupted by stimulant use [4]. Furthermore, BPC-157 has been observed to counteract various behavioral disturbances associated with stimulant exposure, indicating a broader role in mitigating neuroadaptations linked to StUD [5]. Clinically, BPC-157 is often administered subcutaneously at doses between 200-500 mcg daily, typically for 2-4 week cycles, though specific protocols for StUD are still under investigation. You'll find that BPC-157's ability to normalize dopamine activity rather than simply increasing or decreasing it, offers a unique therapeutic advantage.

Oxytocin, often termed the "social hormone," has been explored for its potential to reduce stimulant cravings and improve social functioning in individuals with StUD. Its role in social bonding and stress regulation suggests it could mitigate the social deficits and heightened stress reactivity often seen in stimulant addiction. Studies indicate that intranasal oxytocin can modulate dopamine release in reward pathways and reduce anxiety, potentially decreasing the reinforcing effects of stimulants and improving coping mechanisms [6]. Clinical trials, such as NCT02881177 and NCT03016598, have investigated the tolerability, feasibility, and preliminary effectiveness of intranasal oxytocin administration in individuals with methamphetamine use disorder, with some evidence suggesting it may increase treatment attendance and reduce cravings [7]. Typical intranasal doses in research settings range from 24 IU to 40 IU, administered once or twice daily, often as an adjunct to behavioral therapies.

Beyond specific peptides, the broader class of neuropeptides involved in appetite regulation, such as ghrelin, are gaining attention for their impact on reward and addiction processes. Ghrelin, a hunger-stimulating peptide, has been implicated in mediating the rewarding effects of stimulants, and its modulation could potentially reduce stimulant-seeking behaviors [8]. While still in preclinical stages, targeting these peripheral peptides offers a novel approach to StUD by influencing central reward mechanisms. You'll observe that understanding the interplay between metabolic and reward pathways is crucial for developing comprehensive StUD treatments.

The nuance in utilizing peptides for StUD lies in their ability to address the multifaceted nature of the disorder, often beyond the scope of single-target pharmacotherapies. While traditional approaches often lack effective pharmacological tools for StUD, peptides like BPC-157 can normalize dopamine system dysregulation and mitigate neuroinflammatory processes, and oxytocin can improve social functioning and reduce stress-induced cravings. It's important to view these peptides as potential adjunctive treatments, working synergistically with established behavioral interventions to provide comprehensive support for individuals navigating the complex path of StUD recovery. They are not replacements for detoxification or core addiction treatments but rather complementary tools that can enhance neurobiological resilience.

Comparing peptide interventions to conventional behavioral therapies for StUD highlights their distinct mechanisms. Behavioral therapies, such as cognitive-behavioral therapy (CBT) and contingency management, focus on modifying learned behaviors and developing coping skills. Peptides, conversely, aim to restore neurobiological balance, making it easier for individuals to engage in and benefit from behavioral interventions. For a patient with methamphetamine use disorder experiencing persistent cravings and anhedonia despite consistent behavioral therapy, consider an adjunctive trial of BPC-157 at 250 mcg subcutaneously twice daily for 4 weeks, alongside ongoing therapy, to support dopamine system normalization and mitigate neuroinflammatory processes associated with prolonged stimulant use.

References

[1] Substance Abuse and Mental Health Services Administration. (2023). Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. Retrieved from https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report

[2] Volkow, N. D., et al. (2007). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Annals of the New York Academy of Sciences, 1118(1), 136–150.

[3] Shevchouk, O. T., et al. (2021). An overview of appetite-regulatory peptides in addiction processes; from bench to bed side. Frontiers in Neuroscience, 15, 774050.

[4] Sikiric, P. C., et al. (2002). Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavioral disturbances in rats. Journal of Physiology-Paris, 96(1-2), 119–126.

[5] Sikiric, P. C., et al. (1997). A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to dopamine. European Journal of Pharmacology, 332(1), 1–7.

[6] Lee, M. R., & Weerts, E. M. (2016). Oxytocin for the treatment of drug and alcohol use disorders. Behavioural Pharmacology, 27(7), 603–612.

[7] Stauffer, C. S., et al. (2022). Intranasal Oxytocin for Stimulant Use Disorder Among Male Methamphetamine Users: A Randomized Clinical Trial. Journal of Clinical Psychiatry, 83(1), 21m14018.

[8] Shevchouk, O. T., et al. (2021). An overview of appetite-regulatory peptides in addiction processes; from bench to bed side. Frontiers in Neuroscience, 15, 774050.